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TNF is a proinflammatory cytokine involved in the pathogenesis of chronic inflammatory diseases, but also in metastasis in certain
types of cancer. In terms of therapy, TNF is targeted by anti-TNF neutralising monoclonal antibodies or soluble TNF receptors.
Recently, a novel strategy based on the generation of self anti-TNF antibodies (TNF autovaccination) has been developed. We have
previously shown that TNF autovaccination successfully generates high anti-TNF antibody titres, blocks TNF and ameliorates
collagen-induced arthritis in DBA/1 mice. In this study, we examined the ability of TNF autovaccination to generate anti-TNF antibody
titres and block metastasis in the murine B16F10 melanoma model. We found that immunisation of C57BL/6 mice with TNF
autovaccine produces a 100-fold antibody response to TNF compared to immunisation with phosphate-buffered saline vehicle
control and significantly reduces both the number (Po0.01) and size of metastases (Po0.01) of B16F10 melanoma cells. This effect is
also observed when an anti-TNF neutralising monoclonal antibody is administered, confirming the essential role TNF plays in
metastasis in this model. This study suggests that TNF autovaccination is a cheaper and highly efficient alternative that can block TNF
and reduce metastasis in vivo and trials with TNF autovaccination are already underway in patients with metastatic cancer.
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TNF is an important proinflammatory cytokine involved in normal
physiological immune and inflammatory processes. However,
when inappropriately expressed, TNF also plays a role in the
development of chronic inflammation and diseases associated with
it (Andreakos et al, 2002). More recently, inappropriately
expressed TNF was also shown to play a role in the development
of cancer but in a more complex manner. Thus, in certain cancers
TNF has been shown to induce haemorrhagic necrosis of tumours,
whereas in others it has been shown to promote cancer (Carswell
et al, 1975; Moore et al, 1999). What determines the TNF
procarcinogenic or anticarcinogenic effects is not clear. It may
be that this is dependent on the levels of TNF produced locally or
the type of tumour and cancer involved (Balkwill, 2002).
Previous studies have suggested that one of the main mechan-
isms by which TNF promotes tumour growth is by upregulating
metastasis. TNF activates key molecules involved in metastasis
such as IL-8 (an angiogenic chemokine) and Groa/KC, as well as
matrix metalloproteinases (MMP) and urokinase-plasminogen
activator, molecules involved in ECM degradation and cellular
migration (Wu et al, 1999; Shin et al, 2000). In addition,
recombinant TNF injected into mice inoculated with a methylcho-
lanthrene-induced fibrosarcoma increased the number of lung
metastases (Orosz et al, 1993). Similarly, tumour cell lines infected
with a retrovirus carrying the TNF gene augmented metastatic
activity of the tumour (Quin et al, 1993). In contrast, blocking TNF
using the human p55-IgG fusion protein in a murine B16-BL6
melanoma model reduced the number of metastatic lung tumours
temporarily over 2 weeks but not after 3 weeks, possibly due to
increased immune clearance of the fusion protein (Cubillos et al,
1997).
Monoclonal antibodies and IgG fusion proteins are now an
established approach to blocking TNF. We have previously used
monoclonal antibodies against TNF to ameliorate disease in
animal models of arthritis (Williams et al, 1992) as well as
rheumatoid arthritis in the clinic (Elliot et al, 1994). Similarly,
others have shown that administration of anti-TNF neutralising
antibodies is successful in treating many other diseases such as
Crohn’s disease, psoriasis and spondyloarthropathies (reviewed by
Andreakos et al, 2002). However, there are major drawbacks to the
long-term use of monoclonal antibodies, murine, chimeric or
human, which include a variable degree of immunogenicity and
major costs, $12–15000 p.a. (d7–9000) (Dillman et al, 1994;
LoRusso et al, 1995; Philpott et al, 1995). TNF autovaccination is
an alternative, novel approach that circumvents the problem of
immunogenicity and cost of nonautologous antibodies. It is based
on the generation of autologous human autoantibodies by
immunisation with a self-antigen to which a T-cell epitope has
been added (Dalum et al, 1997). Autoantibodies against TNF are
raised by immunisation with recombinant TNF protein containing
inserted hen egg lysozyme (HEL) or ova albumin (OVA) epitopes.
This leads to a T helper response specific for the foreign parts of
the recombinant molecule and allows the generation of antibodies
against TNF that neutralise and eliminate it (Dalum et al, 1999).
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sWhen we previously used TNF autovaccination in a murine
collagen-induced arthritis model, we found that this resulted in the
generation of high titres of anti-TNF antibodies that ameliorated
the disease and decreased the severity of arthritis (Dalum et al,
1999).
In this study, we examined whether blockade of TNF could
reduce metastasis in the murine B16F10 melanoma model (Poste
et al, 1980) and compared the efficacy of anti-TNF monoclonal
antibodies and the TNF autovaccination technology in reducing
metastasis. Our results indicate that both the conventional anti-
TNF monoclonal antibody treatment and TNF autovaccination are
successful in reducing the number and size of lung metastases in
this model and supports the use of these agents in clinical trials in
patients with metastatic cancer.
MATERIALS AND METHODS
Immunisation with TNF autovaccination
The immunisation regime was first developed in 4- to 5-week-old
male DBA/1 mice as described in our previous study in collagen-
induced arthritis (Dalum et al, 1999). C57BL/6 mice (4-week old)
(12/group) were immunised intradermally at the base of the tail
with 100mg of TNF autovaccine in phosphate-buffered saline (PBS)
emulsified with complete Freund’s adjuvant (CFA), in a volume of
100ml (Figure 1). Three subsequent boosts with TNF autovaccine
in incomplete Freund’s adjuvant (IFA) were performed at two-
weekly intervals. In the immunisation study, the control used was
HEL in CFA and three boosters in IFA and the blood samples were
taken prior to study commencement and at two-weekly intervals
thereafter, for 12 weeks. For the B16F10 metastasis model, mice
were immunised with PBS in CFA/IFA as a control. After 3 weeks,
the mice were killed, lung tumours counted, and the diameter
measured in two perpendicular planes. To reduce biased selection
in the B16F10 melanoma metastasis model, the treatments were
blinded coding them A and B prior to injection and the codes
broken at the end of the experiment after the data were collected
and analysed.
Blood samples were taken prior to immunisation and prior to
tumour insertion. On killing the animals at the end of the
experiments, a terminal bleed was also undertaken. The blood was
allowed to clot and then centrifuged at 12000r.p.m. for 5min and
the top layer of sera removed. The serum was stored at  201C
prior to use in immunological assays to determine antibody levels.
The experiments were carried out according to Protocol 8 on
License PPL 70 3831, issued by The Home Office Animal
Procedures Section, London and adhered to the UKCCR guidelines
(Workman et al, 1998).
Treatment with Anti-TNF monoclonal antibodies
C57BL/6 mice (6-week old) were injected intraperitoneally (i.p.)
with 500mg100ml
 1 of anti-TNF monoclonal antibodies (CV1q)
three times per week or PBS. Again to reduce biased selection, the
treatments were blinded coding them A and B prior to insertion
into the mice and the code was broken after the data were collected
and analysed. The monoclonal antibodies were a rat mouse fusion
protein (gift from Dr DB Scallon, Centocor, Malvern, USA). The
day after the initial injection, 10
5 B16F10 murine melanoma cells in
200ml of PBS were injected into the tail vein of each mouse. After 3
weeks, the mice were killed and the lung tumours counted and the
diameter measured as described above.
Antibody detection assays
Microtitre plates were coated with 1mgml
 1 of TNF in PBS at
100mlwell
 1 and incubated overnight at 41C. The plates were
blocked with 2% bovine serum albumin (BSA) in PBS
(200mlwell
 1) for 1h at 251C and washed with 0.5% Tween in
PBS after this and all subsequent steps. A measure of 100ml of one
in three serial dilutions of serum samples and the positive and
negative control sera were incubated for 1h at 251C. The detection
antibody (100mlwell
 1) was diluted in 0.5% BSA in PBS and
incubated for 1h at 251C. A sheep anti-mouse polyclonal detection
antibody conjugated to horseradish peroxidase was used. These
samples were developed with a peroxidase substrate system TMB,
the reaction was stopped with 1 M H2SO4 and absorbance read at
450nm. Since standard known amounts of antibodies to these
antigens were unavailable, eight serial dilutions of sample sera
were made and their titres taken as the dilution that gave an OD
corresponding to that of the negative control sera. The negative
control sera were from unimmunised mice and the positive control
sera were pooled sera from previously immunised mice that had
been tested by ELISA and found to have antibodies that bound
TNF.
Cell culture and detection of KC
B16F10 murine melanoma cells were grown at 371Ci n5 %C O 2 in
RPMI supplemented with 10% foetal bovine serum (BioWhit-
taker), penicillin (100Uml
 1) and streptomycin (100mgml
 1).
B16F10 cells were plated in 96-well plates at 2 10
6 cellsml
 1 and
200mlwell
 1. The cells were stimulated with LPS at 10mgml
 1;
some cells were further stimulated with murine TNF (mTNF) at 10
or 100ngml
 1 and other cells with media as a control. The plates
were incubated 371C. Supernatants were removed at 24 and 72h
and stored at  201C for immunological detection assays. KC was
measured by ELISA as described previously (Sarawar et al, 2002).
Detection range for the KC was 10000–4.5ngml
 1.
02468
IM-1 IM-2 IM-3 IM-4
Time (weeks)
Immunisation 
Blood sampling 
Terminal bleed 
Tumour insertion 
Figure 1 Experimental design and study calendar showing immunisation
protocol and tumour insertion. The diagram shows the time points for
immunisation of TNF autovaccine, blood sampling, injection of the B16F10
cells (tumour insertion) and termination of the experiment at the terminal
bleed.
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TNF autovaccination induces high levels of anti-TNF
autoantibody production
We investigated the ability of the novel TNF autovaccination to
induce high anti-TNF antibody titres. We immunised C57BL/6
mice with the TNF autovaccine in the presence of CFA/IFA and
compared the antibody responses to mice immunised with HEL in
CFA/IFA. We found that in the TNF autovaccination group, the
anti-TNF antibody titres started rising at week 4 peaked at week 8
and reached plateau levels thereafter (Figure 2). This was
compared to the HEL control group that had no anti-TNF
antibody response. This was similar to the antibody response seen
in BALB/c and CH3 mice (Dalum et al, 1999), but different from
the biphasic antibody response seen at 6 and 10 weeks in DBA/1
mice after immunisation with TNF autovaccine (data not shown).
Anti-TNF monoclonal antibodies on lung metastases in the
B16F10 melanoma model
First, to confirm the role of TNF in metastases in the B16F10
melanoma model, we used an anti-TNF neutralising antibody,
CV1q. Mice were treated i.p. with either PBS or anti-TNF
monoclonal antibodies (CV1q), and then B16F10 melanoma
cells were injected into the tail vein. We found that mice treated
with anti-TNF monoclonal antibodies had significantly less
and smaller metastases compared to the mice treated with PBS
(Figure 3A and B).
TNF blockade through immunisation using a novel TNF
autovaccine on lung metastases in vivo in the B16F10
melanoma model
Having shown that blocking TNF can have an effect on metastasis,
we examined the effect of immunisation with TNF autovaccine in
the B16F10 melanoma model in three independent experiments.
Mice were immunised with TNF autovaccine or PBS in CFA and
boosted with IFA. The B16F10 melanoma cells were injected into
the tail vein of each mouse 4 weeks after their first immunisation
and the tumours were allowed to grow for 3 weeks.
We found that the group of mice immunised with the TNF
autovaccine showed significant reduction in metastatic lesions
compared with those treated with PBS (Figure 4A). The sizes of
the metastases were also significantly reduced in the mice
immunised with TNF autovaccine compared to the PBS
control group (see Figure 4B). The reason for not using HEL with
CFA as the control was that in previous experiments it had led to
increased murine morbidity. The morbidity may have been due to
the use of a strong antigen such as HEL with CFA inducing
ulcerations on the surface of the animals; this was not seen with
TNF autovaccination. Upon killing the animals, a terminal bleed
was carried out. In these experiments, blood was also sampled
from mice prior to immunisation and prior to tumour implanta-
tion. The anti-TNF antibodies were then measured in the
sera using an ELISA-based detection system (Figure 5). We found
that the anti-TNF titres in the TNF autovaccination group
increased dramatically by the end of the experiment unlike the
PBS control group.
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Figure 2 Anti-TNF antibody response in mice immunised with TNF
autovaccine. Two groups of 4-week-old C57BL/6 mice (n¼8) were initially
immunised with 100mg TNF autovaccine or HEL in CFA then, at two-
weekly intervals, boosted three times with 100mg of the same antigen in
IFA. Serum samples were taken prior to immunisation and every 2 weeks
thereafter. The TNF antibody levels were measured in an ELISA. The titre
values were calculated as the dilution of serum, which corresponded to
titres from nonimmunised mice. The mean levels7s.e.m. are shown. This is
representative of two independent experiments.
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Figure 3 Effect of anti-TNF monoclonal antibody treatment in the
B16F10 metastatic model. C57BL/6 mice (8-week old) (anti-TNF group)
were treated with i.p. injections of anti-TNF monoclonal antibodies (CV1q)
500mg100ml
 1mouse
 1. The PBS group were treated with 100ml PBS i.p.
All mice were treated three times per week. Following their first injection,
the mice were injected i.v. with 10
5 B16F10 cells. The mice were killed 3
weeks later, the lung metastases counted and mean diameters measured
with callipers. The median is shown and the Kruskal–Wallis and Dunn’s
multiple comparison nonparametric test calculates significance, *Po0.01
and **Po0.001.
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production in B16F10 cells
In conjunction with the in vivo experiments, the ability of mouse
recombinant TNF to induce the expression of cytokines/chemo-
kines such as IL-6, IL-1, VEGF, GMCSF and KC, and also TNF was
examined as this could account for some of the metastatic effects
of TNF. However, we found no detectable IL-6, IL-1, VEGF,
GMCSF or endogenous TNF when B16F10 cells were left
unstimulated or stimulated with TNF and or LPS in vitro, in vivo
this may differ. In contrast, the chemokine KC (the murine
equivalent of human MGSA/Groa), previously described to play a
role in metastasis (Smith et al, 1998), could be detected by ELISA
when B16F10 cells were cultured for 24 and 72h in vitro with either
TNF or anti-TNF neutralising monoclonal antibodies. TNF
increased KC production above background levels after 72h when
100mgml
 1 of TNF was added to B16F10 cultures. Anti-TNF
neutralising antibodies added to B16F10 cells did not reduce KC
(Figure 6). Interestingly, we found that under certain circum-
stances TNF can induce KC expression at 24 and 72h. Thus, by
adding 10mgml
 1 LPS at the onset of the culture, the production of
KC was increased in B16F10 cells both at 24 and 72h (Figure 6).
The addition of TNF in these cultures greatly upregulated KC
production in a dose-dependent manner. This suggested that in
combination with certain stimuli, TNF might have a synergistic
effect in inducing KC in B16F10 cells. Surprisingly, anti-TNF had
no effect in the LPS-induced KC production in these cultures,
suggesting that LPS did not increase endogenous TNF production
in the B16F10 cells.
DISCUSSION
The B16F10 murine melanoma model has been used by a number
of groups to examine the process of metastasis (Poste et al, 1980).
It offers the advantage of injecting B16F10 melanoma cells into
mice, which can metastasise to the lungs. Tumours in the lungs are
then readily visible as B16F10 cells are pigmented.
In this study, we used the model to investigate the role of TNF in
promoting metastasis and the ability of the TNF autovaccination
technology to generate high titre anti-TNF autoantibodies to
inhibit TNF function in vitro. We have also used TNF auto-
vaccination to generate high titres of anti-TNF antibodies in vivo
and ameliorate collagen-induced arthritis in DBA/1 mice (Dalum
et al, 1999). We found that in C57BL/6 mice, TNF autovaccination
also induced high levels of anti-TNF antibodies in the serum that
plateaued 8 weeks after immunisation (Figure 2). This was similar
to the anti-TNF antibody titres induced by TNF autovaccination in
BALB/c and CH3 mice (Dalum et al, 1999), but different from the
biphasic antibody response seen in DBA/1 mice after immunisa-
tion with TNF autovaccination. The reason for this is not clear, but
may simply be due to differences in the binding and presentation
of epitopes between the distinct MHC class II haplotypes.
Alternatively, this may be due to the different types of assay used
to detect anti-TNF antibodies. In DBA/1 mice, only biologically
active anti-TNF antibodies were measured using a bioassay that
quantifies their ability to inhibit TNF cytotoxicity, whereas in
BALB/c and CH3 mice a biochemical receptor assay was used and
for the C57BL/6 mice all anti-TNF antibodies were measured using
an ELISA assay. In terms of clinical trials of TNF autovaccination
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Figure 4 Lung metastases in mice immunised with TNF autovaccine in
the B16F10 melanoma model. C57BL/6 mice (4-week old) (n¼12/
treatment group) were immunised i.m. with 100mg TNF autovaccine or
PBS in CFA and boosted three times at two-weekly intervals in IFA. B16F10
cells (10
5) in 200ml of PBS were injected into their tail veins at 4 weeks
post initial immunisation. At 7 weeks, the mice were killed and the lungs
excised. The numbers of lung metastases were counted (A) and six
randomly selected tumours measured with calipers (B). Each group was
compared to the PBS control and the one-Way ANOVA test was used to
evaluate results. The mean and P-values for each group are shown. A
representative of three independent experiments is shown, *Po0.01.
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Figure 5 Anti-TNF antibody titres in mice immunised with TNF
autovaccination in the B16F10 metastatic model. C57BL/6 mice (4-week
old) (n¼12/treatment group) were immunised and tumour cells inserted
as described in Figure 3. Mice were bled at 0.4 and 7 weeks. The TNF
antibody levels were measured in an ELISA. The titre values were
calculated as the dilution, which gave an OD equal to nonimmunised mice.
Mean and s.e.m. for each group of mice are shown and the results were
evaluated using one-way ANOVA comparing each group to the PBS
control, *Po0.05 and **Po0.001.
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sin patients, the potential variability in antibody responses will be
undesirable as it may result in variability in efficacy or make
interpretation of data difficult. However, this problem should we
hope be circumvented by using promiscuously binding T helper
epitopes in the recombinant vaccines.
The induction of high levels of anti-TNF antibodies reduced the
number of metastases reaching and establishing themselves in the
lungs as well as their size in the B16F10 murine melanoma model
when compared to mice immunised with PBS in CFA. Prior to this,
we ensured that blocking TNF by a known mechanism, mono-
clonal antibodies to TNF, could also reduce tumour metastasis. For
this, we examined the effect of treating mice with anti-TNF
monoclonal antibodies upon tumour insertion and had a reduction
in the lung metastases compared to the PBS-treated control group.
Further support for this comes from findings of Cubillos et al
(1997), who used a human TNF receptor fusion protein in a B16-
BL6 melanoma model. Although it was found that the human
soluble TNF fusion protein significantly inhibited lung metastases,
this effect was short lived possibly due to the immunogenicity of
the human protein increasing its clearance. In our system, the TNF
monoclonal antibody, CV1q, is a rat/mouse fusion protein, and as
the two species share more similarity, the rat portion does not
produce as strong an anti-rat immune response when injected into
mice. TNF autovaccination generated autologous antibodies and
therefore the antibodies would not have been recognised and
cleared by the mouse immune response. Both the autoantibodies
generated by immunisation with TNF autovaccine and the anti-
TNF monoclonal antibodies reduced the levels of metastases
measured after 3 weeks, which shows that their effect lasted longer
than that seen with the human TNF receptor fusion protein
(Cubillos et al, 1997). The optimal time for tumour insertion was
based on the previous data by Dalum et al (1999) and on the
immunisation of C57BL/6 mice (Figure 2). These data showed that
the anti-TNF antibodies measured in mice treated with TNF
autovaccination were present from 4 to 10 weeks. Others have
shown a subsequent decline in anti-TNF antibody levels at 3–6
months (data not shown). Consequently, the time for tumour
insertion was chosen as 4 weeks to correspond to the rise in
antibody levels as seen in Figure 5 in which the anti-TNF
antibodies were measured in mice with melanoma. Unfortunately,
the examination of the TNF autovaccine in established tumours in
the B16F10 melanoma model was not possible because of two
reasons. First, the B16F10 melanoma model is an acute rapidly
progressing model that develops metastases within 2–3 weeks. As
TNF autovaccination requires 4–6 weeks to induce optimal TNF
autoantibodies, the tumour burden by that time would have been
too great, with many mice already dead or in great pain for the
procedure to be ethically acceptable. Second, most of the TNF
tumour-promoting effects that have been described concern
processes that occur during metastasis. Therefore, our main
purpose was to investigate if blocking TNF by TNF autovaccina-
tion had an effect on the establishment of metastasis from cells in
circulation.
We then investigated potential mechanisms involved in the
reduction of metastases seen with TNF autovaccination. Owing to
the small amounts of serum obtained from each mouse, we were
unable to perform a range of cytokine evaluations. The only
inflammatory marker measured was serum amyloid P, which
showed no difference in levels between the treated groups (data not
shown). As we were unable to examine any cytokines in the mice
sera, we examined the effects of blocking TNF in vitro. We found
that at high doses of TNF or in the presence of LPS, TNF
upregulates KC in B16F10 cells. Interestingly, studies of mice that
had their primary tumours removed surgically and were then
injected with LPS or saline had increased lung metastases in the
LPS injected group, indicating that LPS may activate mechanisms
involved in the metastatic processes (Pidgeon et al, 1999).
Furthermore, in vivo and in vitro studies have shown that LPS
can increase vascular permeability, tumour invasion as well as
increase inducible nitric oxide synthase and MMP2 production, two
factors known to play a role in metastasis (Harmey et al, 2002). It
may be that in vivo LPS or LPS-like pathways also upregulate KC,
although these groups did not measure this. Although LPS may not
be physiologically relevant in this context, our study still
demonstrates that under certain conditions that may be met in
vivo, TNF can upregulate KC production. Certainly, in humans TNF
alone is able to upregulate Groa (the human equivalent of KC) in
keratinocytes (Li and Thornhill, 2000), fibroblasts and human
melanoma cell lines (Shattuck et al, 1994). Interestingly, KC is a
proinflammatory chemokine that has been found to play a key role
in inducing neovascularisation of corneal epithelial cells (Strieter
et al, 1995) and in promoting metastasis in squamous carcinoma
cells (Smith et al, 1998). Thus, part of the effect of blocking TNF by
TNF autovaccination may be due to a decrease in the production of
KC. Decreased KC production, in particular, may result in the
reduced ability of B16F10 cells to invade lung tissue and also reduce
neovascularisation of tumours in the lung, consequently decreasing
the size and numbers of metastatic lesions. In our cell system,
however, we were unable to demonstrate any reduction in KC when
anti-TNF was added to B16F10 cells, which maybe due to
insufficient TNF production by B16F10 cells despite LPS stimula-
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Figure 6 Effects of TNF and LPS on KC production in B16F10 cells. Cells
were plated out in triplicate at 2 10
6mlml
 1 in 200mlwell
 1. To each
well was added 10mgml
 1 LPS, 10 or 100ngml
 1 mTNF, 10mgml
 1
murine anti-TNF monoclonal antibodies or media as a control as shown in
the legend. Supernatants were removed at 24 and 72h to measure KC
levels by ELISA. Statistical significance was measured by the one-way
ANOVA test. These are pooled results from two experiments.
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stion. Therefore, we can only speculate that KC maybe one of the
mechanisms by which blocking TNF reduces metastasis in our in
vivo melanoma model. TNF may also directly affect neovascular-
isation and angiogenesis by upregulating factors such as VEGF as
previously shown in human macrophage cells and synovial cells
from rheumatoid arthritis patients (Paleolog et al, 1998; Kiriakidis
et al, 2003). In vivo, some cancers particularly epithelial tumours
produce TNF; however, in other cancers, stromal cells are a source
of TNF that can then have an effect on the tumours (Balkwill, 2002).
Overall, our study shows that although metastasis is a complex
multisystem process involving a large number of different
molecules, in the B16F10 murine melanoma model TNF plays an
important and rate-limiting role. This is likely to be partly due to
its ability to increase the expression of prometastatic molecules
such as KC. In addition, our study demonstrates that the TNF
autovaccination technology is a very efficient strategy in producing
anti-TNF antibodies in mice and preventing in that way the
number and size of metastases. This strategy is also safe in this
experimental system as no adverse effects or increase in tumour
growth or metastasis was seen. We are currently conducting a
phase I human clinical trial to evaluate the effect of blocking TNF
by using TNF autovaccination in patients with a variety of cancers.
Results from these trials are eagerly awaited. If this strategy is
found to be effective in human trials, it would be a cost-effective
alternative to infusing monoclonal antibodies and more conve-
nient for patients who would possibly only require three injections
for a 3-month benefit.
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